Episode
Community Link by GoodRx | TWIRx
- Podcast
- Pharmacy Podcast Network
- Published
- Jul 24, 2026
- Duration seconds
- 1812
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/pharmacy-podcast-network-945715/episodes/community-link-by-goodrx-twirx/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/pharmacy-podcast-network-945715/community-link-by-goodrx-twirx.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Independent pharmacies are facing growing reimbursement uncertainty, especially when dispensing high-cost brand medications such as GLP-1 therapies. In this exclusive Pharmacy Podcast Network special feature, we examine how GoodRx Community Link provides independent pharmacies with predictable pricing and favorable economics across both brand and generic medications, ultimately helping pharmacies remain solvent while providing consumers affordable prescription prices. Todd Eury is joined by David Graziano, Head of Retail Network at GoodRx, and Tom DePietro, independent pharmacy owner at DePietro’s Pharmacy, for a practical discussion about the pressures affecting independent pharmacy and the need for reimbursement models that support pharmacy viability. The conversation explores how Community Link supports brand medications through manufacturer-funded savings that flow back to the pharmacy through GoodRx, while the manufacturer covers the administrative fee. For generic medications, the program uses a NADAC-based cost-plus model intended to provide clearer visibility into reimbursement. Listeners will also hear how independent pharmacies are impacted by rising deductibles, prior authorizations, narrow formularies, cash-pay growth, and increased competition. David and Tom discuss the importance of transparent pricing, digital engagement, streamlined fulfillment, personalized patient care, and sustainable economics for local pharmacies. Key discussion points include: The financial risk of dispensing high-cost brand medications like GLP-1s Predictable reimbursement for brands and generics The role of manufacturer-funded savings for brand medications NADAC-based cost-plus pricing for generics Pharmacy access to GLP-1 cash-pay programs Competing through service, technology,…